RxDoctor Payments Data

Brandi Vincent, APRN

Family · Enfield, NCNPI 1851071591

Payments from drug & device makers

$528in general payments, 2019–2025

Across 24 payments — averaging $21.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$125
  • Corcept Therapeutics$114
  • AstraZeneca$41
  • Organon$40
  • Novo Nordisk$33
  • Harmony Biosciences LLC$31
  • plus $145 from 8 others

What the payments were for

  • Food & beverage$528100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$528 in reported general payments places this provider in the 55th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$921
Medicare patients
32
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$82,839
JardianceEmpagliflozin92$76,937
LinzessLinaclotide74$58,747
EliquisApixaban53$57,804
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$56,800
FarxigaDapagliflozin Propanediol63$50,890
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$30,135
VelphoroSucroferric Oxyhydroxide12$19,704
XareltoRivaroxaban25$19,702
RybelsusSemaglutide12$16,486
EntrestoSacubitril/Valsartan12$15,642
SymbicortBudesonide/Formoterol Fumarate42$11,151
Tresiba Flextouch U-100Insulin Degludec17$9,376
TradjentaLinagliptin13$8,946
Breo ElliptaFluticasone/Vilanterol18$8,032

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$33$99,32586 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$41$92,176138 claims
Boehringer IngelheimJardiance, Tradjenta$18$85,883105 claims
GSKTrelegy Ellipta, Breo Ellipta$125$64,83289 claims
Astellas Pharma US IncMyrbetriq$20$7,92213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,522 family providers in North Carolina.

Other family in Enfield

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →